We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
301
CALL
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-1,308
Closed -$13.7M
BMRN icon
302
PUT
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-475
Closed -$4.98M
CLDX icon
303
CALL
Celldex Therapeutics
CLDX
$2.77B
– –
-298
Closed -$7.01M
CLDX icon
304
PUT
Celldex Therapeutics
CLDX
$2.77B
– –
-16
Closed -$373K
ESPR
305
DELISTED
Esperion Therapeutics
ESPR
– –
-19,000
Closed -$423K
EW icon
306
Edwards Lifesciences
EW
$47.6B
– –
-18,321
Closed -$506K
EXEL icon
307
PUT
Exelixis
EXEL
$13.9B
– –
-280
Closed -$158K
EYPT icon
308
PUT
EyePoint Inc
EYPT
$1.02B
– –
-34
Closed -$165K
HALO icon
309
PUT
Halozyme
HALO
$9.72B
– –
-840
Closed -$1.46M
IMNN icon
310
PUT
Imunon
IMNN
$6.35M
– –
0
– -$105K
IMUX icon
311
CALL
Immunic
IMUX
$182M
– –
-6
Closed -$2.59M
INO icon
312
CALL
Inovio Pharmaceuticals
INO
$79.8M
– –
-333
Closed -$2.68M
INO icon
313
Inovio Pharmaceuticals
INO
$79.8M
– –
-51,599
Closed -$4.16M
IONS icon
314
CALL
Ionis Pharmaceuticals
IONS
$9.35B
– –
-1,159
Closed -$7.18M
IOVA icon
315
CALL
Iovance Biotherapeutics
IOVA
$2.23B
– –
-2,453
Closed -$1.89M
IWM icon
316
iShares Russell 2000 ETF
IWM
$80.9B
– –
-294,400
Closed -$33.1M
KPRX icon
317
Kiora Pharmaceuticals
KPRX
$11.3M
– –
-42
Closed -$624K
LAB icon
318
CALL
Standard BioTools
LAB
$326M
– –
-3,312
Closed -$3.58M
LXRX icon
319
Lexicon Pharmaceuticals
LXRX
$1.02B
– –
-67,710
Closed -$710K
MBOT icon
320
Microbot Medical
MBOT
$115M
– –
-114
Closed -$77K
MCRB icon
321
CALL
Seres Therapeutics
MCRB
$48M
– –
-3
Closed -$235K
LITS
322
Lite Strategy Inc
LITS
$33.6M
– –
-10,000
Closed -$320K
MGNX icon
323
CALL
MacroGenics
MGNX
$235M
– –
-114
Closed -$353K
MGNX icon
324
PUT
MacroGenics
MGNX
$235M
– –
-80
Closed -$248K
MNKD icon
325
MannKind Corp
MNKD
$1.28B
– –
-127,181
Closed -$727K
11 12
13
14 15

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.